RE: Great news3 Oct 2025 12:37
In vivo whole animal high-throughput drug screening platform to explore new anti-cancer uses of Gallium Maltolate
Imaging Biometrics®, LLC, (IB) a Wisconsin-based biotechnology company, and Vivan Therapeutics, a UK leader in personalized cancer medicine, today announces a strategic research and commercial partnership to evaluate gallium maltolate in new oncologic indications.
Under the agreement, Imaging Biometrics will supply gallium maltolate, with support from its trusted partner, Gallixa®, LLC, for evaluation using Vivan's proprietary in vivo avatar cancer models. These highly customized models mirror a broad spectrum of tumor molecular profiles and are tested through Vivan's state-of-the-art high-throughput platform, enabling rapid and scalable assessment of investigational compounds.
Gallium maltolate, a compound that has already shown promise in glioblastoma, will now be evaluated across a broad spectrum of tumor molecular profiles. The initial focus will be on colorectal cancer, while also extending to other challenging malignancies, including pancreatic, lung, and additional gastrointestinal cancers. The goal is to identify its therapeutic activity either as a single agent or in combination with existing drugs, potentially expanding its clinical utility.